Accelerate HCP Detection With a High Precision Immunoassay
App Note / Case Study
Published: June 20, 2025

Credit: bio-techne
Residual host cell proteins (HCPs) impact the safety and efficacy of biologics. Yet, traditional assays often require time-consuming steps and are burdened by limited sensitivity and the risk of matrix interference.
The need for reproducible, streamlined detection methods has never been greater.
This app note highlights how a microfluidic immunoassay simplifies HCP detection using integrated reagents and automation.
Download this app note to explore:
- Faster, more reproducible HCP monitoring throughout bioprocess workflows
- Correlation with benchmark ELISA data for process consistency
- High assay sensitivity and automated setup, reducing manual variability
Fast and Reproducible Host
Cell Protein Detection
with Simple Plex Assays on Ella
Introduction
Host cell proteins (HCPs) are generated by the host
organism during the production of recombinant
therapeutic proteins or biologics and are a major
component of process-related impurities. During
purification, HCPs need to be monitored and reduced
at every step. Residual HCPs that go undetected can
decrease product efficacy, alter its quality and/or risk
triggering an immunogenic reaction when the drug is
administered to the patient.
To meet increasing business demands and safety
standards, fast and reproducible detection of HCPs
is essential during the manufacturing process of
a biotherapeutic. However, accurate in-process
reporting is often complicated by varying amounts
of HCPs present throughout bioproduction—initial
process pools may consist of high levels of HCPs,
whereas final pools typically amount to lower levels.
This means you’ll need to carefully and extensively
dilute samples at each stage of purification to ensure
detection within the dynamic range of your assay.
Moreover, the sensitivity of your assay should
especially enable the detection of low levels of HCPs
that may be present in final pools. Lastly, look out for
the presence of large amounts of recombinant protein
product, which creates an intricate sample matrix that
can interfere with your ability to accurately measure
low abundance HCPs.
In this application note, we pair Simple Plex™ Assays
on Ella™ with Cygnus Technologies third generation
(3G) Chinese Hamster Ovary (CHO) antibodies to
demonstrate utility for accurately and efficiently
detecting and quantifying the presence of HCP
contaminants from bioprocess samples. We also
demonstrate that Simple Plex CHO HCP, 3G-1
assay data has a near perfect correlation with data
generated using the gold standard Cygnus CHO HCP,
3G ELISA (F550-1).
Why Pair Ella with Cygnus CHO HCP,
3G Antibodies?
All steps of the Simple Plex immunoassay on Ella
are highly automated thanks to the microfluidic
cartridge—everything is preloaded, even the
calibration curve. Just pipette your diluted samples
onto the cartridge, add wash buffer, press Start in the
Ella Runner Software and walk away to the sound of
automatic processing.
Inside the microfluidic cartridge are glass nano
reactors (GNRs), the core of the Simple Plex
immunoassay. In the Simple Plex CHO HCP 3G-1
assay (PN SPCKB-OT-003714), the GNRs are coated
with a polyclonal Cygnus 3G CHO antibody that works
to capture HCPs in your bioprocess samples. That
same antibody is also lyophilized in the cartridge to
act as the detection reagent.
Using Cygnus Technologies CHO HCP
3G Antibodies for Automated Host Cell
Protein Measurements
S I M P L E P L E X A S S A Y S
B I O P R O C E S S I N GThe Cygnus CHO antibody and ELISA kit (Cygnus
Technologies PN F550-1) have been evaluated for
reactivity to more than 1,000 individual HCPs present
in CHO strains by state-of-the-art Antibody Affinity
Extraction™ (AAE™) and mass spectrometry methods.
When paired with Ella and the three GNRs within each
channel of the microfluidic cartridge, you’ll get both
broad detection coverage to the most relevant HCPs
and automatically obtain triplicate results for every
sample. Moreover, the assay provides sub-ng/mL
detection giving you superior assay sensitivity and
data reproducibility throughout the manufacturing
process. Setup takes just 10 to 15 minutes and
you’ll get fully processed and analyzed results in 75
minutes!
Comparison of Ella with Cygnus CHO HCP
3G ELISA Kit, F550-1: Assay Range of
Detection and Sensitivity
The majority of biotherapeutic proteins are
manufactured within mammalian cell-line systems, of
which CHO strains are the predominant cell lines used
for production, and a common originating source of
HCP impurities. Although no compulsory limit has
been set for the HCP level permitted, <100 ng of HCPs
per 1 mg of the drug substance (PPM) is generally
considered acceptable1.
The gold standard Cygnus CHO HCP ELISA Kit, 3G
(F550-1) uses the same HCP polyclonal antibody and
lot number on either side of the “sandwich” and was
used herein as a benchmark for the refined Simple
Plex CHO HCP, 3G-1 Assay. To begin to demonstrate
the utility of the Simple Plex CHO HCP, 3G-1 Assay
in this setting, we compared the dynamic range of
Simple Plex Assays with that of the Cygnus CHO HCP
ELISA (FIGURE 01).
When plugging the Cygnus CHO HCP antibody into
the Simple Plex Assay on Ella, which uses a built-in
fluorescent detection system, the dynamic range of
detection for the traditional Cygnus CHO HCP 3G
Assay was expanded from 1–100 ng/mL to 0.4–625
ng/mL (FIGURE 01).
FIGURE 01. Standard curve of the Simple Plex CHO HCP, 3G-1 Assay (orange) and conventional Cygnus CHO HCP,
3G ELISA (blue). The Simple Plex CHO HCP, 3G-1 Lower Limit of Quantitation (LLOQ) and Upper Limit of Quantitation
(ULOQ) are indicated on the standard curve.
F I G U R E // 0 1
Comparison of standard curves
F I G U R E K E Y
CHO HCP 3G-1
ELISA 3G
0.01 0.01
Units
1000
1
100
10
Concentration (ng/mL)
LLOQ
ULOQ
1 10 100 1000 10000
02Standard curves for the colorimetric Cygnus ELISA
were produced by running all standards in triplicate
followed by absorbance detection using a microtiter
plate reader spectrophotometer with dual wavelength
capability at 450 nm and 650 nm.
Initial culture harvest samples contain high levels
of HCPs which must be reduced by many orders of
magnitude to reach acceptable levels in the final drug
product. Routine monitoring of HCP clearance during
downstream monoclonal antibody (mAb) purification
using a highly sensitive method is necessary to
comply with International Council for Harmonisation
of Technical Requirements for Pharmaceuticals for
Human Use (ICH) guidelines1. In FIGURES 02 and
03, we demonstrate that HCP levels measured by the
Simple Plex 3G-1 assay strongly correlate (R2=0.982)
with those obtained by the Cygnus CHO HCP ELISA,
3G throughout the purification process.
FIGURE 02. Four industrial purification processes were profiled using both the 3G plate ELISA (dark blue) and
the 3G-1 Simple Plex assay (light blue). These processes were measured at multiple steps (X-Axis) to show the
elimination of CHO HCP from the drug product. Across each process the Simple Plex assay showed the same fold
reduction in CHO HCP as the plate ELISA.
F I G U R E // 02
Detection of HCPs during bioproduction with Simple Plex 3G-1 and 3G ELISA
F I G U R E K E Y
Simple Plex 3G-1
ELISA 3G
Process Sample #1
pg/mL CHO HCP
1
10
1,000
100,000
1E+09
10,000,000
Process
Step 1
Process
Step 2
Process
Step 3
Process Sample #2
pg/mL CHO HCP
1
10
1,000
100,000
1E+09
10,000,000
Process
Step 1
Process
Step 2
Process
Step 3
Process Sample #3
pg/mL CHO HCP
1
10
1,000
100,000
1E+09
10,000,000
Process
Step 1
Process
Step 2
Process
Step 3
Process Sample #4
pg/mL CHO HCP
1
10
1,000
100,000
1E+09
10,000,000
Process
Step 1
Process
Step 2
Process
Step 3
03Spike Recovery of In-Process Pools with Simple Plex Assays
To demonstrate assay performance, mAb in-process samples of varying
matrices were spiked with a low, medium or high concentration of HCP
antigen concentrate, 3G (Cygnus Technologies, F553X). To interrogate
the breadth of the assay range, we chose 7.55 ng/mL, 22.2 ng/mL and 114
ng/mL of HCP (FIGURE 04).
FIGURE 03. The aggregated Simple Plex
and ELISA data from the four purification
processes were plotted and a linear fit
was applied to the data set. The Simple
Plex 3G-1 Assay and the 3G ELISA showed
a nearly perfect correlation (R2=0.9822)
across multiple steps of the purification
processes.
F I G U R E // 03
Linear correlation of 3G-1 Simple Plex and plate ELISA assays
y = 0.9884x
R2 = 0.9822
3G ELISA (pg/mL)
100 1,000 1E+09
3G-1 Simple Plex Assay
100
1,000
10,000
100,000
1E+06
1E+07
1E+08
1E+09
10,000 100,000 1E+06 1E+07 1E+08
FIGURE 04. In-process pooled samples
were spiked with known concentrations of
HCP antigen concentrate, and the percent
HCP recovered was determined for each
spike via the Simple Plex CHO HCP,
3G-1 Assay. Average percent recovery
for the low, medium and high spike
concentrations is indicated above each
bar for that respective in-process pool.
F I G U R E // 04
Spike recovery of in-process pools with Simple Plex Assays
F I G U R E K E Y
7.55 ng/mL
22.2 ng/mL
114 ng/mL
Percent Recovery
0
Process
Sample 1
Process
Sample 2
Process
Sample 3
Process
Sample 4
20%
40%
60%
80%
100%
120%
140%
115%
94% 94%
91%
04When taken in aggregate, the sample performance
showed good linearity across 5 logs of dilution and a
large range of incorporated matrix (FIGURE 05). This
demonstrates that the sensitive nature of Cygnus
CHO HCP, 3G reagents translates well to the robust
performance of the Simple Plex Assay format on Ella.
Simple Plex Assay Precision
Ella’s hands-off CHO HCP, 3G-1 immunoassay
workflow consistently delivers high-quality,
reproducible data. To examine assay precision, HCP
levels present within in-process pooled samples
of a mAb at four progressive stages of purification
were measured. Inter-assay CV values for triplicate
analyses ranged from 2% to 5%, attesting to Ella’s
ability to report the same concentration from
separately run cartridges (TABLE 01).
Sample Linearity of Multiple In-Process
Pools with Simple Plex Assays
To examine the ability of Simple Plex Assays to
accurately quantify HCP levels across multiple mAb
cultures and dilution ranges, six pooled in-process
samples were assessed for linearity across four
dilutions. Initial culture dilutions were based on values
that were predicted by the Cygnus CHO HCP ELISA,
3G Kit, F550-1 to fall within the linear range of the
Simple Plex CHO HCP, 3G-1 Assay. All samples were
then serially diluted 1:2, 1:4, 1:8 and 1:16. The percent
difference between each sample value and the
previous dilution was then calculated.
Each in-process mAb sample showed good linearity
at all four dilutions tested, with all percent differences
falling between 80–120% (FIGURE 05). The initial
dilution of these samples, as recommended by the
Cygnus CHO HCP ELISA, 3G Kit, F550-1 ranged from
1:2 to 1:50,000.
FIGURE 05. All six process samples showed good linearity across four different dilutions. All samples were within the acceptable range of
80%-120%.
F I G U R E // 05
Sample linearity from harvest material to drug product
Serial Dilution Factor
Serial Dilution Linearity
0 2
Sample Linearity
0%
20%
40%
60%
80%
100%
120%
140%
160%
4 6 8 10 12 14 16 18
Total Dilution Factor
Sample LInearity Across
the Purification Process
0 10
Sample Linearity
0%
20%
40%
60%
80%
100%
120%
140%
160%
100 1,000 10,000 1E+05 1E+06
05detection achievable with Simple Plex assays is
particularly useful for HCP detection, as samples
need fewer dilutions to meet the linear range of the
assay. With Ella, you’ll get an extended linear range
and improved precision with the same excellent
sample performance you get with the Cygnus CHO
HCP ELISA Kit, 3G.
R E F E R E N C E S
1. The International Conference on Harmonization of
Technical Requirements for Registration of Pharmaceuticals
for Human Use (ICH) guidance Q9 Quality Risk Management.
Available online at https://www.fda.gov/science-research/
guidancedocuments-including-information-sheetsandnotices/ich-guidance-documents. Updated June 2006,
Accessed October 28, 2019.
2. Improving Chinese hamster ovary host cell protein ELISA
using Ella: An automated microfluidic platform. KV ManenBrush, J Zeitler, JR White, P Younge, S Willis, and M Jones,
GlaxoSmithKline, Biopharmaceutical Analytical Sciences,
Biotechniques, 2020; 69: 00–00, 10.2144/btn-2020-0074.
TA B L E // 0 1
Precision comparison of Simple Plex CHO HCP, 3G-1 Assays
MAB Process In-Process Pool 2
(HCP, ng/ml)
In-Process Pool 3
(HCP, ng/ml)
In-Process Pool 4
(HCP, ng/ml)
Final Pool
(HCP, ng/ml)
Replicate 1 4,630 600 246 7.95
Replicate 2 4,810 568 244 7.75
Replicate 3 5,130 621 246 8.3
Average 4,856.7 598.7 245.3 8
Standard Deviation 0.23 0.22 0.29 0.075
CV % 5% 4% 2% 5%
TABLE 01. Triplicate assay values of HCP levels in Process Pool 2, Process Pool 3, Process Pool 4 and the Final Pool were analyzed via the
Simple Plex CHO HCP, 3G-1.
Conclusion
Analysis of CHO HCP with the Simple Plex 3G-1
Assay is a robust alternative to the conventional HCP
ELISA approach. Ella is an automated immunoassay
platform that eliminates the hands-on steps that come
with running a traditional ELISA. You’ll significantly
decrease time to result and reduce human error, both
factors that adversely impact assay reproducibility
and team productivity. These attributes make Ella an
ideal tool for industry environments where a good
manufacturing practice (GMP) system is in place. In
other words, Ella satisfies the demands of timely data
generation for maintaining efficient production and
overcomes the lengthy investigations and sample
retests that often result from human error2.
You also get unmatched assay sensitivity and
highly reproducible results, which ensures that
you get the high-quality data required to meet
regulatory standards for HCP monitoring throughout
bioproduction workflows. The improved range of
Explore All Simple Plex Assays
Scan the QR Code or visit:
bio-techne.com/reagents/simple-plex-immunoassays/assay-menu
For research use or manufacturing purposes only. Trademarks and registered trademarks are the property of their respective owners.
Global Developer, Manufacturer, and Supplier of High-Quality Reagents,
Analytical Instruments, and Precision Diagnostics.
INCLUDES R&D Systems™ Novus Biologicals™ Tocris Bioscience™ ProteinSimple™ ACD™ ExosomeDx™ Asuragen® Lunaphore™
6571180007
Brought to you by

Download the Application Note for FREE Now!
Information you provide will be shared with the sponsors for this content. Technology Networks or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.
Experiencing issues viewing the form? Click here to access an alternate version